THIS CA UPDATE HAS BEEN SENT TO THE FOLLOWING:

COUNTIES:

☒ Imperial
☒ Riverside/San Bernardino
☒ Los Angeles
☐ Orange
☒ Sacramento
☒ San Diego

LINES OF BUSINESS:

☒ Molina Medi-Cal Managed Care
☐ Molina Medicare Options Plus
☐ Molina Dual Options Cal MediConnect Plan (Medicare-Medicaid Plan)
☐ Molina Marketplace (Covered CA)

PROVIDER TYPES:

☒ **Medical Group/ IPA/MSO**

Primary Care
☒ IPA/MSO
☒ Directs

Specialists
☒ Directs
☒ IPA

☒ **Hospitals**

Ancillary
☐ CBAS
☒ SNF/LTC
☐ DME
☐ Home Health
☐ Other

FOR QUESTIONS CALL PROVIDER SERVICES:
(855) 322-4075, Extension:

Los Angeles/Orange Counties
X111113 X123071
X127657

Riverside/San Bernardino Counties
X127684 X120618

Sacramento County
X121360

San Diego County
X121805 X121401
X127709 X121413
X123006 X121599

Imperial County
X125682 X125666

Medi-Cal Drug Utilization Review (DUR) Educational Article – Updated Adverse Effects from Fluoroquinolones

This is an advisory notification to Molina Healthcare of California (MHC) network providers regarding updated Adverse Effects from Fluoroquinolones.

On December 20, 2018, the U.S. Food and Drug Administration (FDA) issued a warning that fluoroquinolones administered orally or intravenously may increase the risk of ruptures of an aortic aneurysm or aortic dissections, which are rare but serious events that can lead to dangerous bleeding or even death. The FDA requires inclusion of the new risks in the prescribing information and patient Medication Guide for all fluoroquinolones. Health care professionals should not prescribe fluoroquinolones to patients at increased risk unless there are no other treatment options available. People at increased risk include those with a history of blockages or aneurysms of the aorta or other blood vessels, high blood pressure, certain genetic disorders that involve blood vessel changes (for example, Marfan syndrome or Ehlers-Danlos syndrome), and the elderly.

In order to minimize risk to patients with no alternative treatment options to fluoroquinolones, health care professionals should consider the following actions:

- Advise all patients taking fluoroquinolones to seek immediate medical treatment for any symptoms associated with aortic aneurysm or dissection.
- Stop fluoroquinolone treatment immediately if a patient reports side effects suggestive of aortic aneurysm or dissection.
- Report side effects involving fluoroquinolones or other medications to the FDA MedWatch program.

The FDA has previously communicated the following safety information associated with fluoroquinolones:

- July 2018 – significant decreases in blood sugar and certain mental health side effects.
- July 2016 – disabling side effects of the tendons, muscles, joints, nerves, and central nervous system.

- May 2016 – restricting use for certain uncomplicated infections.
- August 2013 – peripheral neuropathy.
- July 2008 – tendinitis and tendon rupture.

To read the full safety announcement, which includes a summary of findings from epidemiological studies and cases from the FDA Adverse Event Reporting System (FAERS) database, refer to the "FDA Drug Safety Communication:

FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients" article found on the Drug Safety and Availability page of the FDA website at https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics.

QUESTIONS

If you have any questions regarding the notification, please contact your Molina Provider Services Representative at (855) 322-4075. Please refer to the extensions on page one.